Symbols / ADIL
ADIL Chart
About
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.20M |
| Enterprise Value | -1.87M | Income | -8.05M | Sales | — |
| Book/sh | 4.72 | Cash/sh | 4.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -0.04 | PEG | — |
| P/S | — | P/B | 0.61 | P/C | — |
| EV/EBITDA | 0.24 | EV/Sales | — | Quick Ratio | 3.99 |
| Current Ratio | 4.34 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -15.32 | EPS next Y | -70.15 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -79.36% |
| ROE | -155.01% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.11M |
| Shs Float | 954.95K | Short Float | 0.99% | Short Ratio | 0.87 |
| Short Interest | — | 52W High | 32.50 | 52W Low | 2.70 |
| Beta | 1.24 | Avg Volume | 24.87K | Volume | 13.39K |
| Target Price | $26.00 | Recom | Strong_buy | Prev Close | $2.87 |
| Price | $2.88 | Change | 0.34% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$26.00
Mean price target
2. Current target
$2.70
Latest analyst target
3. DCF / Fair value
$-62.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.70
Low
$8.00
High
$50.00
Mean
$26.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | up | Maxim Group | Hold → Buy | $2 |
| 2024-11-14 | init | Rodman & Renshaw | — → Buy | $8 |
- Addiction-focused Adial Pharma to speak at Oppenheimer investor conference - Stock Titan ue, 17 Feb 2026 14
- Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com ue, 17 Feb 2026 14
- Why ADIL Stock Price Differs Across Trading Platforms 2026 - Bitget Wed, 11 Feb 2026 07
- What insider trading reveals about ADIL stock - Earnings Growth Report & Daily Oversold Stock Bounce Ideas - mfd.ru Fri, 13 Feb 2026 09
- Why Is Adial Pharmaceuticals Stock (ADIL) Down Today? - TipRanks hu, 05 Feb 2026 08
- Maxim Group Upgrades Adial Pharmaceuticals (ADIL) - Nasdaq ue, 30 Sep 2025 07
- Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why - Yahoo Finance hu, 10 Jul 2025 07
- Market Movers | Winners: ADIL, ASST, RLYB | Losers: OBAI, GEOS, PFSA - Trefis Fri, 06 Feb 2026 04
- Maxim Group Maintains Adial Pharmaceuticals(ADIL.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛 Sat, 14 Feb 2026 17
- Why Did Adial Pharmaceuticals Stock Plunge Over 20% After Hours Today? - Stocktwits ue, 03 Feb 2026 08
- Adial reverse split slashes shares, cashes out fractions to stay on Nasdaq - Stock Titan ue, 03 Feb 2026 08
- Is ADIL stock a value trap - Market Trend Review & AI Forecast Swing Trade Picks - mfd.ru Mon, 16 Feb 2026 04
- Market Movers | Winners: ASST, ADIL, RLYB | Losers: EAF, ERNA, ANEB - Trefis Sat, 07 Feb 2026 04
- All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy - Yahoo Finance Mon, 01 Sep 2025 07
- Adial Pharmaceuticals (NASDAQ: ADIL) enters $2.86M inducement at $0.31 exercise price - Stock Titan Wed, 26 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -8.78K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.82M | -6.89M | -10.86M | -15.86M |
| TotalUnusualItems | -4.46M | 0.00 | 522.00K | -1.83M |
| TotalUnusualItemsExcludingGoodwill | -4.46M | 0.00 | 522.00K | -1.83M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.20M | -7.00M | -10.80M | -19.42M |
| ReconciledDepreciation | 565.00 | 564.00 | 564.00 | 55.11K |
| EBITDA | -8.28M | -6.89M | -10.86M | -17.69M |
| EBIT | -8.28M | -6.89M | -10.86M | -17.74M |
| NetInterestIncome | 178.66K | 69.78K | 63.34K | 6.54K |
| InterestIncome | 178.66K | 69.78K | 63.34K | 6.54K |
| NormalizedIncome | -8.73M | -7.00M | -10.80M | -17.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.20M | -5.12M | -12.73M | -19.42M |
| TotalExpenses | 8.28M | 6.89M | 10.86M | 17.74M |
| TotalOperatingIncomeAsReported | -8.28M | -6.89M | -10.86M | -19.29M |
| DilutedAverageShares | 4.85M | 1.42M | 1.00M | 743.55K |
| BasicAverageShares | 4.85M | 1.42M | 1.00M | 743.55K |
| DilutedEPS | -2.72 | -3.60 | -12.71 | -26.00 |
| BasicEPS | -2.72 | -3.60 | -12.71 | -26.00 |
| DilutedNIAvailtoComStockholders | -13.20M | -5.12M | -12.73M | -19.42M |
| NetIncomeCommonStockholders | -13.20M | -5.12M | -12.73M | -19.42M |
| NetIncome | -13.20M | -5.12M | -12.73M | -19.42M |
| NetIncomeIncludingNoncontrollingInterests | -13.20M | -5.12M | -12.73M | -19.42M |
| NetIncomeDiscontinuousOperations | 0.00 | 1.88M | -1.94M | |
| NetIncomeContinuousOperations | -13.20M | -7.00M | -10.80M | -19.42M |
| TaxProvision | 0.00 | 0.00 | 0.00 | -94.08K |
| PretaxIncome | -13.20M | -7.00M | -10.80M | -19.52M |
| OtherIncomeExpense | -5.09M | -183.72K | 522.00K | -1.78M |
| OtherNonOperatingIncomeExpenses | -75.04K | 10.16K | 46.49K | |
| SpecialIncomeCharges | -4.46M | 0.00 | 522.00K | -1.83M |
| OtherSpecialCharges | 4.46M | |||
| WriteOff | 0.00 | 1.55M | ||
| ImpairmentOfCapitalAssets | 1.55M | |||
| RestructuringAndMergernAcquisition | -522.00K | 281.71K | ||
| EarningsFromEquityInterest | -552.18K | -193.88K | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 178.66K | 69.78K | 63.34K | 6.54K |
| InterestIncomeNonOperating | 178.66K | 69.78K | 63.34K | 6.54K |
| OperatingIncome | -8.28M | -6.89M | -10.86M | -17.74M |
| OperatingExpense | 8.28M | 6.89M | 10.86M | 17.74M |
| ResearchAndDevelopment | 3.23M | 1.27M | 1.95M | 8.40M |
| SellingGeneralAndAdministration | 5.06M | 5.62M | 8.91M | 9.34M |
| GeneralAndAdministrativeExpense | 5.06M | 5.62M | 8.91M | 9.34M |
| OtherGandA | 5.06M | 5.62M | 8.91M | 9.34M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 6.47M | 1.66M | 1.07M | 837.87K |
| ShareIssued | 6.47M | 1.66M | 1.07M | 837.87K |
| TotalDebt | 207.38K | 256.96K | ||
| TangibleBookValue | 4.06M | 4.08M | 3.27M | 2.80M |
| InvestedCapital | 4.07M | 4.08M | 3.28M | 3.51M |
| WorkingCapital | 3.08M | 2.55M | 2.99M | 3.74M |
| NetTangibleAssets | 4.06M | 4.08M | 3.27M | 2.80M |
| CapitalLeaseObligations | 207.38K | 256.96K | ||
| CommonStockEquity | 4.07M | 4.08M | 3.28M | 3.51M |
| TotalCapitalization | 4.07M | 4.08M | 3.28M | 3.51M |
| TotalEquityGrossMinorityInterest | 4.07M | 4.08M | 3.28M | 3.51M |
| StockholdersEquity | 4.07M | 4.08M | 3.28M | 3.51M |
| RetainedEarnings | -82.00M | -68.80M | -63.67M | -50.94M |
| AdditionalPaidInCapital | 86.06M | 72.88M | 66.95M | 54.43M |
| CapitalStock | 6.47K | 1.66K | 1.07K | 20.95K |
| CommonStock | 6.47K | 1.66K | 1.07K | 20.95K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 975.86K | 653.08K | 2.46M | 3.97M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 665.44K | 1.24M |
| OtherNonCurrentLiabilities | 492.00K | 1.01M | ||
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 665.44K | ||
| NonCurrentDeferredLiabilities | 22.90K | 23.40K | ||
| NonCurrentDeferredTaxesLiabilities | 22.90K | 23.40K | ||
| LongTermDebtAndCapitalLeaseObligation | 150.55K | 207.38K | ||
| LongTermCapitalLeaseObligation | 150.55K | 207.38K | ||
| CurrentLiabilities | 975.86K | 653.08K | 1.79M | 2.72M |
| OtherCurrentLiabilities | 376.13K | 9.68K | ||
| CurrentDebtAndCapitalLeaseObligation | 56.83K | 49.59K | ||
| CurrentCapitalLeaseObligation | 56.83K | 49.59K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 405.25K | 421.37K | 761.51K | 520.79K |
| PayablesAndAccruedExpenses | 570.61K | 231.71K | 653.23K | 2.14M |
| CurrentAccruedExpenses | 272.21K | 104.32K | 376.82K | 1.86M |
| Payables | 298.40K | 127.39K | 276.41K | 286.19K |
| DuetoRelatedPartiesCurrent | 48.27K | 24.06K | 0.00 | |
| AccountsPayable | 250.13K | 103.33K | 276.41K | 286.19K |
| TotalAssets | 5.04M | 4.74M | 5.73M | 7.47M |
| TotalNonCurrentAssets | 985.18K | 1.54M | 952.87K | 1.01M |
| OtherNonCurrentAssets | 948.39K | |||
| NonCurrentPrepaidAssets | 0.00 | |||
| InvestmentsAndAdvances | 981.83K | 1.53M | 0.00 | |
| LongTermEquityInvestment | 981.83K | 1.53M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 3.35K | 3.91K | 4.48K | 709.01K |
| OtherIntangibleAssets | 3.91K | 4.48K | 460.04K | |
| Goodwill | 248.97K | 248.97K | ||
| NetPPE | 244.42K | 304.36K | ||
| GrossPPE | 244.42K | 304.36K | ||
| OtherProperties | 50.42K | 58.15K | ||
| BuildingsAndImprovements | 194.00K | 246.21K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 4.06M | 3.20M | 4.78M | 6.46M |
| OtherCurrentAssets | 308.24K | 371.60K | 349.44K | 389.50K |
| AssetsHeldForSaleCurrent | 0.00 | 428.70K | ||
| PrepaidAssets | 428.70K | 9.93K | ||
| CashCashEquivalentsAndShortTermInvestments | 3.75M | 2.83M | 4.00M | 6.06M |
| CashAndCashEquivalents | 3.75M | 2.83M | 4.00M | 6.06M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.92M | -6.81M | -11.19M | -12.01M |
| IssuanceOfCapitalStock | 4.02M | 749.94K | 9.12M | 11.75M |
| CapitalExpenditure | -64.61K | |||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 3.75M | 2.83M | 4.00M | 6.06M |
| BeginningCashPosition | 2.83M | 4.00M | 6.06M | 4.40M |
| ChangesInCash | 923.44K | -1.17M | -2.06M | 1.66M |
| FinancingCashFlow | 7.85M | 4.13M | 9.13M | 13.64M |
| CashFlowFromContinuingFinancingActivities | 7.85M | 4.13M | 9.13M | 13.64M |
| NetOtherFinancingCharges | -1.66K | |||
| ProceedsFromStockOptionExercised | 3.82M | 3.38M | 1.86K | 1.89M |
| NetCommonStockIssuance | 4.02M | 749.94K | 9.12M | 11.75M |
| CommonStockIssuance | 4.02M | 749.94K | 9.12M | 11.75M |
| InvestingCashFlow | 0.00 | 1.50M | 0.00 | -34.02K |
| CashFlowFromContinuingInvestingActivities | 0.00 | 1.50M | 0.00 | -34.02K |
| NetOtherInvestingChanges | 1.50M | |||
| NetBusinessPurchaseAndSale | 0.00 | 30.59K | ||
| SaleOfBusiness | 0.00 | 30.59K | ||
| NetPPEPurchaseAndSale | 0.00 | -64.61K | ||
| PurchaseOfPPE | 0.00 | -64.61K | ||
| OperatingCashFlow | -6.92M | -6.81M | -11.19M | -11.95M |
| CashFromDiscontinuedOperatingActivities | -1.00M | -2.59M | ||
| CashFlowFromContinuingOperatingActivities | -6.92M | -5.80M | -8.59M | -11.95M |
| ChangeInWorkingCapital | 386.14K | -794.21K | -1.17M | 1.46M |
| ChangeInOtherCurrentLiabilities | -49.59K | -37.34K | ||
| ChangeInPayablesAndAccruedExpense | 322.78K | -772.05K | -1.22M | 1.17M |
| ChangeInAccruedExpense | 151.77K | -612.64K | -1.24M | 1.52M |
| ChangeInPayable | 171.01K | -159.41K | 15.83K | -353.77K |
| ChangeInAccountPayable | 171.01K | -159.41K | 15.83K | -353.77K |
| ChangeInPrepaidAssets | 63.36K | -22.16K | 49.99K | 335.29K |
| OtherNonCashItems | 4.54M | 51.90K | -522.00K | 281.71K |
| StockBasedCompensation | 796.83K | 1.75M | 3.37M | 4.24M |
| AssetImpairmentCharge | 0.00 | 1.55M | ||
| DeferredTax | -502.00 | -94.08K | ||
| DeferredIncomeTax | -502.00 | -94.08K | ||
| DepreciationAmortizationDepletion | 565.00 | 564.00 | 564.00 | 55.11K |
| DepreciationAndAmortization | 565.00 | 564.00 | 564.00 | 55.11K |
| AmortizationCashFlow | 565.00 | 564.00 | 564.00 | 565.00 |
| AmortizationOfIntangibles | 565.00 | 564.00 | 564.00 | 565.00 |
| Depreciation | 59.94K | 54.54K | ||
| OperatingGainsLosses | 552.18K | 193.88K | -22.13K | |
| EarningsLossesFromEquityInvestments | 552.18K | 193.88K | 0.00 | |
| GainLossOnSaleOfPPE | 0.00 | 6.95K | ||
| NetIncomeFromContinuingOperations | -13.20M | -7.00M | -10.80M | -19.42M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ADIL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|